|Bid||60.71 x 1000|
|Ask||61.00 x 1800|
|Day's Range||54.04 - 62.50|
|52 Week Range||14.01 - 99.95|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021 - Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.38|
Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Meanwhile, the industry indicator, iShares NASDAQ Biotechnology Index (NASDAQ: IBB), only returned a total of 41%. The most mind-boggling aspect of Editas is that the company already has a staggering $4.1 billion market cap -- despite having no therapies out on the market.
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
Wayne Gretzky hung up his hockey sticks a long time ago. Although Gretzky's quote has become something of a cliche, it nonetheless remains highly relevant in many areas -- including investing. For investors, the idea is the same concept that Gretzky articulated years ago: Focus on what's going to happen in the future.